Bridging antifungal prophylaxis with micafungin in hematopoietic stem cell transplantation: a retrospective analysis

Figures & data

Table 1. Characteristics of the patients and HSCT.

Characteristics of the patients and HSCT
Sex
Male	42
Female	31
Age, median (range), years	28(8–53)
History of fungal infection
Yes	26
No	47
Disease type
Acute myeloid leukemia	26
Acute lymphoblastic leukemia	28
Hybrid acute leukemia	2
Myelodysplastic syndrome	5
Chronic myeloid Leukemia/myelomonocytic leukemia	4
Non-Hodgkin’s lymphoma	6
Aplastic anemia	2
Conditioning regimen
Reduced-intensity conditioning	65
TBI-based conditioning	8
GVHD prophylaxis
Cyclosporine A + methotrexate	29
Cyclosporine A + mycophenolate mofetil	8
Cyclosporine A + methotrexate + mycophenolate mofetil	36
Type of allo-HSCT
MSD transplant	29
Haploidentical transplant	22
Umbilical cord blood transplant	8
Well-matched unrelated donor transplant	14
Dose of micafungin usage/day
50/100/150mg	25/36/12
White blood cells engraftment time (days)	11(9–30)
Platelet engraftment time (days)	13(8–79)

ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; NHL: Non-Hodgkin’s lymphoma; AA: Aplastic anemia; TBI: total body irradiation; CsA: Cyclosporine A; MTX: methotrexate; MMF: mycophenolate mofetil; MSD: matched-sibling donor; WM-URD: well-matched unrelated donor transplant; WBC: white blood cells; PLT: platelet.

Figure 1. The fungal-free survival after HSCT.

Table 2. Clinical data of two patients with failure of micafungin prophylaxis during neutropenia period.

Case	1	2
Underlying disease	Hybrid acute leukemia	ALL
History of fungal infection	Yes	Yes
Type of HSCT	Haploid	WM-URD
Micafungin dose	100 mg	150 mg
The time of IFI diagnosis	+11	0d
IFI grade	Probable	Probable
Outcome	Successful	Successful
IFI-related death	No	No

Abbreviations: ALL: acute lymphoblastic leukemia; WM-URD: well-matched unrelated donor transplant.